Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deprescribing of antidepressants: development of indicators of high-risk and overprescribing using the RAND/UCLA Appropriateness Method.

BMC medicine·2024
Same author

Correction: Siegel et al. PEN-13: A New Generic 13-Item Questionnaire for Measuring Patient Enablement (German Version). <i>Int. J. Environ. Res. Public Health</i> 2019, <i>16</i>, 4867.

International journal of environmental research and public health·2024
Same author

The New PRISCUS List.

Deutsches Arzteblatt international·2023
Same author

"Consensus Based" Alternative Recommendations Are Disconcerting.

Deutsches Arzteblatt international·2023
Same author

Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland.

JAMA network open·2022
Same author

Educating physicians on strong opioids by descriptive versus simulated-experience formats: a randomized controlled trial.

BMC medical education·2022
Same journal

The Prevalence of Hospitalized Cases of Necrotizing Fasciitis: Anatomical Distribution, Amputations, and In-Hospital Mortality, 2019-2024.

Deutsches Arzteblatt international·2026
Same journal

Subclinical Atrial Fibrillation: Detection, Stroke Risk, and Treatment.

Deutsches Arzteblatt international·2026
Same journal

Fewer Premature Births After Assisted Reproduction.

Deutsches Arzteblatt international·2026
Same journal

Femoral Artery Pseudoaneurysm Due to Stent Fracture in PAOD.

Deutsches Arzteblatt international·2026
Same journal

Pain-Adapted Full Weight-bearing After Ankle Fracture Surgery: A Multicenter, Pragmatic, Single-armed Prospective Study.

Deutsches Arzteblatt international·2026
Same journal

Popliteal Artery Entrapment Syndrome.

Deutsches Arzteblatt international·2026
See all related articles

Related Experiment Video

Updated: May 7, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Does the pharmaceutical industry influence guidelines?: two examples from Germany.

Gisela Schott1, Claudia Dünnweber, Bernd Mühlbauer

  • 1Drug Commission of the German Medical Association, Berlin.

Deutsches Arzteblatt International
|October 1, 2013
PubMed
Summary
This summary is machine-generated.

Drug company manipulation of clinical trial data influenced German medical guidelines for gabapentin and efalizumab. Independent data access and conflict-free guideline development are crucial for reliable medical recommendations.

More Related Videos

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Related Experiment Videos

Last Updated: May 7, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Area of Science:

  • Medical guideline development
  • Pharmaceutical industry influence
  • Clinical trial data integrity

Background:

  • Clinical guideline recommendations rely on trial findings and expert opinions.
  • Drug company influence on these factors is a significant concern.
  • Two case studies illustrate potential data manipulation and its impact.

Purpose of the Study:

  • To investigate if manipulated gabapentin data influenced German clinical guidelines.
  • To analyze the impact of financial ties on guideline recommendations using efalizumab as a case study.
  • To assess the role of industry influence in medical practice recommendations.

Main Methods:

  • Analysis of judicially ordered expert review of gabapentin data manipulation.
  • Systematic search for manipulated gabapentin publications in AWMF guidelines.
  • Comparative analysis of psoriasis treatment guidelines with and without author conflicts of interest.

Main Results:

  • Manipulated gabapentin data was incorporated into AWMF guideline recommendations.
  • Efalizumab received a more favorable assessment in an S3 guideline compared to a NICE guideline.
  • The S3 guideline recommended efalizumab for psoriasis, citing good evidence and quality of life improvements.

Conclusions:

  • Ensuring public access to all trial data is essential for independent evaluation.
  • Guidelines should be developed by authors and organizations free from conflicts of interest.
  • Independent oversight is necessary to maintain the integrity of clinical recommendations.